Affiliation: Mayo Clinic
Kurokawa C, Iankov I, Galanis E. A key anti-viral protein, RSAD2/VIPERIN, restricts the release of Measles virus in infected cells. Virus Res. 2019;: pubmed publisher
..These results provide important information regarding the interaction between MV and the innate immune system, as well as implications for the design of oncolytic MV platforms. ..
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen P, et al
. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012;13:e196-204 pubmed publisher
..The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology. ..
Galanis E, Bateman A, Johnson K, Diaz R, James C, Vile R, et al
. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001;12:811-21 pubmed
..In summary, the viral fusogenic membrane glycoproteins (GALV and the MV-F + MV-H combination) are potent therapeutic transgenes with potential utility in the gene therapy of gliomas. ..
Galanis E, Buckner J, Maurer M, Reid J, Kuffel M, Ames M, et al
. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs. 2005;23:495-503 pubmed
..Initial disease stabilization occurred in approximately 38% of the patients, with median duration of 2 months. Enzyme-inducing anticonvulsants did not affect the pyrazoloacridine metabolism. ..
Galanis E, Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B, et al
. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70:875-82 pubmed publisher
..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients. ..
Galanis E, Buckner J, Maurer M, Kreisberg J, Ballman K, Boni J, et al
. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-304 pubmed
..High levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment. These findings should be validated in other studies of mTOR inhibitors. ..
Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther. 2010;88:620-5 pubmed publisher
..In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics. ..
Galanis E, Atherton P, Maurer M, Knutson K, Dowdy S, Cliby W, et al
. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75:22-30 pubmed publisher
..Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy. ..
Kurokawa C, Geekiyanage H, Allen C, Iankov I, Schroeder M, Carlson B, et al
. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol. 2017;131:41-48 pubmed publisher
..In conclusion, alisertib displays significant antitumor activity against primary GBM lines and xenografts, including patient derived GBM lines resistant to bevacizumab; these data support clinical translation in GBM. ..